CST, 15096S, BCL9 Antibody

Polyclonal Antibody for studying BCL9. Validated for Western Blotting. Highly specific and rigorously validated in-house, BCL9 Antibody (CST #15096) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity BCL9 Antibody recognizes endogenous levels of total BCL9 protein. This antibody also cross-reacts with an unidentified protein of 21 kDa in some cell lines. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding His138 of human BCL9 protein. Antibodies are purified by protein A and peptide affinity chromatography. Background B-cell CLL/lymphoma 9 protein (BCL9) is a widely conserved adaptor protein that functions as a transcriptional co-activator in the canonical Wnt signaling pathway (1,2). BCL9 is a core component of a nuclear protein complex (BCL9, LEF/TCF, β-catenin and PYGO) that regulates the transcription of Wnt-dependent target genes (3). Research studies show that disrupting the interaction between BCL9 and β-catenin suppresses oncogenic Wnt signaling, suggesting a potential avenue for therapeutic intervention in Wnt-mediated cancers (4). BCL9 promotes association of PYGO with the tail of histone H3 that has been methylated at lysine 4 (H3K4me), suggesting a specific chromatin remodeling function for BCL9 in the Wnt signaling pathway (5). Research studies in colon epithelium and adenocarcinomas suggest that BCL9 is required to mediate Wnt-dependent stem cell behaviors, such as epithelial-mesenchymal transition (6). Crystallography studies revealed that BCL9 contains a β-catenin binding site that is distinct from the majority of known β-catenin binding partners, making it an attractive target for therapeutic drug development (7). Alternate Names B cell CLL/lymphoma 9; B-cell CLL/lymphoma 9; B-cell CLL/lymphoma 9 protein; B-cell lymphoma 9 protein; Bcl-9; BCL9; BCL9 transcription coactivator; LGS; MGC131591; Protein legless homolog Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 149 SOURCE: Rabbit